Detection of cancer-related proteins in fresh-frozen ovarian cancer samples using laser capture microdissection

Methods in Molecular Biology

Volumn 414, Issue , 2007, Pages 35-45

  Silasi, Dan Arin ^a   Alvero, Ayesha B ^a   Mor, Jechiel ^a   Chen, Rui ^a   Fu, Han Hsuan ^a   Montagna, Michele K ^a   Mor, Gil ^a  

^a NONE

Author keywords

FasL; Laser capture microdissection; MyD88; Ovarian cancer; XIAP

Indexed keywords

BIRC4 PROTEIN, HUMAN; FAS LIGAND; FASLG PROTEIN, HUMAN; MYD88 PROTEIN, HUMAN; MYELOID DIFFERENTIATION FACTOR 88; TUMOR MARKER; TUMOR PROTEIN; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

ARTICLE; CRYOPRESERVATION; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LASER; METHODOLOGY; MICRODISSECTION; OVARY TUMOR; PATHOLOGY; ULTRAMICROTOMY;

CRYOPRESERVATION; CRYOULTRAMICROTOMY; FAS LIGAND PROTEIN; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LASERS; MICRODISSECTION; MYELOID DIFFERENTIATION FACTOR 88; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 37849034400     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Article

References (12)

1. Jones MB, Krutzsch H, Shu H, Zhao Y, Liotta LA, Kohn EC, Petricoin EF 3rd. Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer. Proteomics 2(1):76-84, 2002.
2. Agiostratidou G, Sgouros I, Galani E, Voulgari A, Chondrogianni N, Samantas E, Dimopoulos MA, Skarlos D, Gonos ES. Correlation of in vitro cytotoxicity and clinical response to chemotherapy in ovarian and breast cancer patients. Anticancer Research 21(1A):455-9, 2001.
3. Emmert-Buck MR, Bonner RF, Smith PD, Chuaqui RF, Zhuang Z, Goldstein SR, Weiss RA, Liotta LA. Laser capture microdissection. Science 274(5289): 998-1001, 1996.
4. Wang VW, Bell DA, Berkowitz RS, Mok SC. Whole genome amplification and high-throughput allelotyping identified five distinct deletion regions on chromosomes 5 and 6 in microdissected early-stage ovarian tumors. Cancer Research 61(10):4169-74, 2001.
5. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin 2003;53:5-26.
6. Hoskins WJ, Perez CA, Young RC, Barakat RR, Markman M, Randall ME. Principles and Practice of Gynecologic Oncology. 4th ed. 2005.
7. Sapi E, Alvero AB, Chen W, O'Malley D, Hao XY, Dwipoyono B, Garg M, Kamsteeg M, Rutherford T, Mor G. Resistance of ovarian carcinoma cells to docetaxel is XIAP dependent and reversible by phenoxodiol. Oncology Research 14(11-12):567-78, 2004.
8. Abrahams VM, Straszewski SL, Kamsteeg M, Hanczaruk B, Schwartz PE, Rutherford TJ, Mor G. Epithelial ovarian cancer cells secrete functional Fas ligand. Cancer Research 63(17):5573-81, 2003.
9. Abrahams VM, Kamsteeg M, Mor G. The Fas/Fas ligand system and cancer: immune privilege and apoptosis. Molecular Biotechnology 25(1): 19-30, 2003.
10. Hardiman G, Jenkins NA, Copeland NG, Gilbert DJ, Garcia DK, Naylor SL, Kastelein RA, Bazan JF. Genetic structure and chromosomal mapping of MyD88. Genomics 45(2):332-9, 1997.
11. Akazawa T, Masuda H, Saeki Y, Matsumoto M, Takeda K, Tsujimura K, Kuzushima K, Takahashi T, Azuma I, Akira S, Toyoshima K, Seya T. Adjuvantmediated tumor regression and tumor-specific cytotoxic response are impaired in MyD88-deficient mice. Cancer Research 64(2):757-64, 2004.
12. Zeisel MB, Druet VA, Sibilia J, Klein JP, Quesniaux V, Wachsmann D. Cross talk between MyD88 and focal adhesion kinase pathways. Journal of Immunology 174(11):7393-7, 2005.